Influences of antidepressant medications on the risk of developing hyperlipidemia in patients with depression by a population-based cohort study and on in vitro hepatic lipogenic-related gene expression
| Autor: | Cheng-Li Lin, Yun-Ping Lim, Jie-Yee Khaw, Yu-Chi Hsiao, Jung-Nien Lai, Tien-Yuan Wu, Ni Tien |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Population Taiwan Gene Expression Hyperlipidemias Comorbidity Cohort Studies Risk Factors Internal medicine Hyperlipidemia medicine Humans cardiovascular diseases Risk factor education Proportional Hazards Models Retrospective Studies education.field_of_study Depression business.industry Incidence Lipogenesis Confounding Hazard ratio Retrospective cohort study medicine.disease Antidepressive Agents Psychiatry and Mental health Clinical Psychology Cohort business Cohort study |
| Zdroj: | Journal of Affective Disorders. 295:271-283 |
| ISSN: | 0165-0327 |
| Popis: | BACKGROUND Depression increases the risk of cardiovascular disease (CVD). The association between antidepressant medications (ADMs) and CVD remains controversial. Hyperlipidemia is a risk factor for CVD. We conducted a nationwide population-based retrospective cohort study to examine depression and ADM use on the risk of developing hyperlipidemia. The effects of ADMs on the expression of lipogenesis-related hepatic genes were also evaluated. METHODS We obtained data from the Longitudinal Health Insurance Database of Taiwan on patients with new-onset depression and a comparison cohort without depression. A Cox proportional hazards regression model was used to analyze the differences in the risk of developing hyperlipidemia between these two cohorts. We also examined the influence of ADMs on the expression of lipogenesis-related hepatic genes. RESULTS After adjustment for comorbidities and confounding factors, the case group (N = 38,322) had a higher risk for hyperlipidemia than that of the control cohort (N = 38,322) [adjusted hazards ratio (aHR) =1.16]. Patients with depression who did not receive ADM therapy exhibited a significantly higher risk of hyperlipidemia (aHR = 1.61). However, in patients with depression treated with ADMs, the risk of developing hyperlipidemia was significantly lowered compared to the patients without ADMs (all aHR < 0.81). Gene expression analysis indicated that ADMs downregulated the expression of lipogenesis-related hepatic genes. LIMITATIONS Unmeasured confounding risk factors for hyperlipidemia might not have been included in the study. CONCLUSIONS ADMs reduced hyperlipidemia risk in patients with depression, partly by downregulating the expression of lipogenesis-related genes and improving the patients' lipid profiles. Early diagnosis and management of hyperlipidemia would further facilitate the prevention of CVD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect